ANAB icon

AnaptysBio

18.97 USD
+0.57
3.10%
At close Apr 2, 4:00 PM EDT
After hours
18.97
+0.00
0.00%
1 day
3.10%
5 days
3.21%
1 month
29.58%
3 months
41.99%
6 months
-45.80%
Year to date
41.99%
1 year
-8.97%
5 years
40.52%
10 years
11.59%
 

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 34

4.93% more ownership

Funds ownership: 111.47% [Q3] → 116.39% (+4.93%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

16% less funds holding

Funds holding: 160 [Q3] → 135 (-25) [Q4]

39% less call options, than puts

Call options by funds: $21M | Put options by funds: $34.3M

48% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 52

58% less capital invested

Capital invested by funds: $1.13B [Q3] → $469M (-$659M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
16%
upside
Avg. target
$39
104%
upside
High target
$51
169%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
JP Morgan
Anupam Rama
23% 1-year accuracy
14 / 61 met price target
121%upside
$42
Overweight
Maintained
5 Mar 2025
HC Wainwright & Co.
Emily Bodnar
18% 1-year accuracy
29 / 161 met price target
16%upside
$22
Neutral
Reiterated
4 Mar 2025
Wells Fargo
Derek Archila
39% 1-year accuracy
12 / 31 met price target
169%upside
$51
Overweight
Maintained
13 Feb 2025
Wedbush
David Nierengarten
33% 1-year accuracy
39 / 117 met price target
111%upside
$40
Outperform
Maintained
7 Feb 2025

Financial journalist opinion

Positive
Zacks Investment Research
1 week ago
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
Neutral
GlobeNewsWire
1 week ago
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Anaptys Announces Stock Repurchase Plan
Negative
Zacks Investment Research
1 month ago
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT Leerink Partners 2025 Global Healthcare Conference, Miami, FL Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT Barclays 27 th Annual Global Healthcare Conference, Miami, FL Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
Anaptys Announces Participation in March Investor Conferences
Positive
Zacks Investment Research
1 month ago
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
1 month ago
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
Neutral
Investors Business Daily
1 month ago
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses Rosnilimab was safe and well tolerated with similar adverse event rates vs.
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Neutral
GlobeNewsWire
1 month ago
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Charts implemented using Lightweight Charts™